Delfi said its technology leverages recent discoveries in the genome-wide fragmentation profiles of cell-free DNA to detect evidence of tumors from blood samples, and also has the capability to pinpoint the location of tumors in the body. Delfi plans to develop a range of products for detecting specific cancers, such as lung cancer, in at-risk individuals, as well as to identify multiple types of cancers in any individual.

The company raised $100 million in a series A financing round led by OrbiMed, with participation from multiple existing and new investors. Delfi will use the funds to expand its team of cancer researchers and validate its technology.